首页> 美国卫生研究院文献>Blood >Clinical Trials and Observations: Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors
【2h】

Clinical Trials and Observations: Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors

机译:临床试验和观察:无关供体脐带血移植后的急性移植物抗宿主病:危险因素分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Acute graft-versus-host disease (GVHD) occurs less frequently after umbilical cord blood transplantation (UCBT). More recent investigations include the use of 2 partially human leukocyte antigen (HLA)–matched UCB units, or double UCB graft, to meet the minimum cell-dose requirement. The purpose of this analysis was to assess the relative risk of acute GVHD in 265 consecutive patients receiving transplants with UCB graft composed of 1 (n = 80) or 2 (n = 185) units. The incidence of grade III-IV acute GVHD was similar between cohorts. However, the incidence of grade II-IV acute GVHD was higher among double UCBT recipients (58 vs 39%, P < .01). Three risk factors for grade II-IV acute GVHD were identified in multiple regression analysis: use of 2 UCB units, use of nonmyeloablative conditioning, and absence of antithymocyte globulin in the conditioning regimen. Transplantation-related mortality (TRM) at 1 year, however, was significantly lower after double UCBT (24 vs 39%, P = .02) even if recipients had grade II-IV acute GVHD (20 vs 39%, P = .05). These data suggest that, despite a higher incidence of grade II acute GVHD in recipients of 2 partially HLA-matched UCB units, there is no adverse effect on TRM. This study is registered at under the identifiers and .
机译:脐血移植(UCBT)后,急性移植物抗宿主病(GVHD)的发生频率降低。最近的研究包括使用2个部分人白细胞抗原(HLA)匹配的UCB单位或双UCB移植物,以满足最低的细胞剂量要求。该分析的目的是评估265名接受UCB移植的连续265例患者的急性GVHD的相对风险,该UCB移植由1(n = 80)或2(n = 185)个单位组成。队列之间III-IV级急性GVHD的发生率相似。但是,双UCBT接受者中II-IV级急性GVHD的发生率更高(58%vs 39%,P <.01)。在多重回归分析中确定了II-IV级急性GVHD的三个危险因素:使用2个UCB单位,使用非清髓性调理和在调理方案中不使用抗胸腺细胞球蛋白。然而,即使接受者具有II-IV级急性GVHD,1年后的移植相关死亡率(TRM)仍显着降低(24 vs 39%,P = .02)(20 vs 39%,P = .05) )。这些数据表明,尽管接受2个部分HLA匹配的UCB单位的II级急性GVHD发生率更高,但对TRM没有不利影响。该研究在的标识符下注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号